...
首页> 外文期刊>Journal of pediatric endocrinology & metabolism: JPEM >Steroid responsive encephalopathy associated with autoimmune thyroiditis (SREAT) in childhood
【24h】

Steroid responsive encephalopathy associated with autoimmune thyroiditis (SREAT) in childhood

机译:儿童类固醇反应性脑病伴自身免疫性甲状腺炎(SREAT)

获取原文
获取原文并翻译 | 示例

摘要

Aim: Steroid responsive encephalopathy with autoimmune thyroiditis (SREAT) is a clinically and electrographi-cally heterogeneous steroid-responsive encephalopathy associated with thyroid autoantibodies. We report an adolescent with SREAT and review PubMed literature relating to childhood.Methods: A 14-year-old boy, without any preceding history of trauma, meningoencephalitis or seizures, was admitted in a comatose state. A similar episode of loss of consciousness 2 months prior with normal neuroimaging and electroencephalogram (EEG) had been followed by behavioral alterations. A year previously, during evaluation for increased appetite and poor weight gain, he was noted to have small goitre with thyroid-stimulating hormone (TSH) 7.26 mlU/L, T3 1.232 nmol/L, and T4 117.63 nmol/L. Routine hemogram, blood biochemistry, thyroid function tests including free hormone levels, ultrasonography thyroid and magnetic resonance imaging were normal. EEG showed diffuse slowing of all waves. Cerebrospinal fluid showed no pleocytosis and electrophoresis showed oligoclonal band. Viral studies and serum N-methyl-D-aspartate receptor antibody levels were negative. Anti-thyroid peroxidase (Anti-TPO) antibodies were raised. Intervention was with intravenous dexamethasone 4 mg every 6 h for 1 week followed by tapering schedule of oral prednisolone over 6 months.Results: He regained consciousness after the second dose of dexamethasone and was discharged on day 7 in a fully conscious and ambulant state on a tapering course of low dose prednisolone for 6 months. He remains euthyroid with normal sensorium and behavior at 18 months follow-up. Only 50 cases below 18 years age were identified amongst 300 PubMed articles up to 31 July 2013. Conclusion: Prompt steroid therapy following early recognition by high clinical suspicion and measurement of antithyroid antibody titers can lead to a favorable prognosis in SREAT.
机译:目的:类固醇反应性脑病伴自身免疫性甲状腺炎(SREAT)是一种临床上和电图上异类固醇反应性脑病,伴有甲状腺自身抗体。我们报道了一名青少年SREAT并审查了与童年有关的PubMed文献。方法:一个14岁的男孩,先前没有任何外伤,脑膜脑炎或癫痫病史,以昏迷状态入院。正常的神经影像学检查和脑电图(EEG)检查前两个月出现了类似的意识丧失事件,之后出现了行为改变。一年前,在评估食欲增加和体重增加不良时,他的甲状腺肿小,甲状腺刺激激素(TSH)为7.26 mlU / L,T3为1.232 nmol / L,T4为117.63 nmol / L。常规血常规,血液生化,甲状腺功能检查(包括游离激素水平),甲状腺超声检查和磁共振成像均正常。脑电图显示所有波的弥散性减慢。脑脊液未见细胞增多,电泳未见寡克隆带。病毒研究和血清N-甲基-D-天冬氨酸受体抗体水平均为阴性。产生了抗甲状腺过氧化物酶(Anti-TPO)抗体。结果是:他每6小时静脉注射地塞米松4 mg,持续1周,随后逐渐减少口服泼尼松龙的疗程,超过6个月。结果:第二剂地塞米松后他恢复了意识,并在第7天以完全清醒和救护的状态出院。小剂量泼尼松龙的减量疗程为6个月。随访18个月,他的甲状腺功能正常,感觉和行为正常。截止到2013年7月31日,在300篇PubMed文章中仅发现了50例18岁以下的病例。结论:在临床高度怀疑和抗甲状腺抗体滴度的早期发现之后,立即进行类固醇治疗可以使SREAT预后良好。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号